Are there papers on transcatheter arterial chemoembolization of hepatocellular carcinoma?

Introduction

Transcatheter arterial chemoembolization (TACE) is a widely used treatment for hepatocellular carcinoma (HCC), particularly for patients with unresectable tumors. This method combines localized chemotherapy with embolization to block the blood supply to the tumor, enhancing the therapeutic effect while minimizing systemic toxicity.

Key Insights

Efficacy and Safety of TACE:
- TACE is effective and safe for treating unresectable HCC, with significant survival benefits and manageable adverse events .
- The 2-year survival rate for patients undergoing TACE is around 75%, with a median overall survival period of 3.1 years.
- Tumor response rates are high, with complete or partial responses observed in a significant proportion of patients .
Factors Influencing Outcomes:
- Tumor size and portal vein invasion are significant predictors of tumor response and survival.
- Child-Pugh class, surgical resection, and radiofrequency ablation after TACE are good prognostic factors for survival.
- The presence of ascites, accumulation of iodized oil in tumor thrombi, and tumor size are important prognostic factors.
Combination Therapies:
- Combining TACE with radiotherapy significantly improves survival and tumor response compared to TACE alone.
- Gene therapy, such as p53 gene therapy combined with TACE, shows promise in managing recurrent HCC.
Innovative Techniques:
- Superselective TACE using three-dimensional rotational angiography can effectively treat HCC while minimizing liver damage in patients with poor liver function.
- Polylactic acid microspheres containing aclarubicin hydrochloride used in TACE show significant antitumor effects with mild systemic toxicity.
Immunological Impact:
- TACE treatment leads to an increase in L-selectinlow CXCR3+ effector T cells, indicating an immunological response that may contribute to its therapeutic effects.

Conclusion

TACE is a well-established, effective, and safe treatment for unresectable hepatocellular carcinoma, with various factors influencing its success. Combining TACE with other therapies, such as radiotherapy or gene therapy, can enhance its efficacy. Innovative techniques and understanding the immunological impact of TACE further contribute to its effectiveness in managing HCC.

Try another search

system thinking

definition of job satisfaction

What are the scientific findings on the benefits of dietary patterns like the Mediterranean diet for longevity?

How do we understand and model the effects of climate change on human societies?

Can reading help with depression?

What are the latest advancements in regenerative medicine and stem cell therapy?

Are there papers on transcatheter arterial chemoembolization of hepatocellular carcinoma?

Summary

Consensus Meter

Introduction

Key Insights

Conclusion

Sources and full results

Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.

Transcatheter arterial chemoembolization is a safe and effective standard treatment for unresectable hepatocellular carcinoma in Asian countries.

Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.

Modified cisplatin-based transcatheter arterial chemoembolization is safe and effective for large hepatocellular carcinomas, with tumor size and portal vein invasion as significant predictors of tumor response and good prognostic factors for survival.

Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride.

Transcatheter arterial chemoembolization using polylactic acid microspheres containing aclarubicin hydrochloride is an effective and tumor-targeting chemotherapy for treating hepatocellular carcinoma.

Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization.

P53 gene therapy combined with transcatheter arterial chemoembolization effectively treats recurrent hepatocellular carcinoma, with no recurrence identified in a 2-month follow-up.

Treatment with transcatheter arterial chemoembolization induces an increase of the L-selectinlow CXCR3+ CD8+ T cell subset in patients with hepatocellular carcinoma

Transcatheter arterial chemoembolization may increase L-selectinlow CXCR3+ effector T cells in patients with hepatocellular carcinoma.

Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

TACE plus radiotherapy significantly improves survival and tumor response in unresectable hepatocellular carcinoma patients, but additional randomized controlled trials are needed before it can be recommended routinely.

Superselective transcatheter arterial chemoembolisation of an unresectable hepatocellular carcinoma using three-dimensional rotational angiography.

Superselective transcatheter arterial chemoembolisation using three-dimensional rotational angiography effectively treats unresectable hepatocellular carcinoma, with minimal treatment-induced liver failure.

Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma

TACE using iodized oil shows promising results in treating unresectable hepatocellular carcinoma, with improved prognosis and a lower risk of death.

Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors.

Chemoembolization is an effective treatment for hepatocellular carcinoma invading the portal veins, with prognostic factors like tumor response, ascites, and iodized oil accumulation in tumor thrombi being key factors.

Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

TACE plus radiotherapy significantly improves survival and tumor response compared to TACE alone for unresectable HCC, with increased incidence of gastroduodenal ulcers and elevated bilirubin levels.

Try another search